Select Language
SIRP alpha
SIRP alpha Overview
| English Name | Signal-regulatory protein alpha | Approved Drugs | 2 |
| Drugs in Clinical Trials | 19 | Target Synonym | SHPS-1，Macrophage fusion receptor，Brain Ig-like molecule with tyrosine-based activation motifs，MFR，Signal-regulatory protein alpha-1，Signal-regulatory protein alpha-2，CD172a，MyD-1 antigen，Sirp-alpha-3，MYD1，SIRPA，Signal Regulatory Protein Alpha，CD172 Antigen-Like Family Member A，Inhibitory Receptor SHPS-1，PTPNS1，SHPS1，SIRP，P84，Brain-Immunoglobulin-Like Molecule With Tyrosine-Based Activation Motifs，Protein Tyrosine Phosphatase， Non-Receptor Type Substrate 1，Tyrosine-Protein Phosphatase Non-Receptor Type Substrate 1，Tyrosine Phosphatase SHP Substrate 1，Signal-Regulatory Protein Alpha-3，Signal-Regulatory Protein Alpha，SHP Substrate 1，CD172a Antigen，Sirp-Alpha-1，Sirp-Alpha-2，MYD-1，Bit，SIRPalpha，SIRPalpha2 |
| Highest Development Stage | Approved | ||
| English Name | Signal-regulatory protein alpha |
| Target Synonym | SHPS-1，Macrophage fusion receptor，Brain Ig-like molecule with tyrosine-based activation motifs，MFR，Signal-regulatory protein alpha-1，Signal-regulatory protein alpha-2，CD172a，MyD-1 antigen，Sirp-alpha-3，MYD1，SIRPA，Signal Regulatory Protein Alpha，CD172 Antigen-Like Family Member A，Inhibitory Receptor SHPS-1，PTPNS1，SHPS1，SIRP，P84，Brain-Immunoglobulin-Like Molecule With Tyrosine-Based Activation Motifs，Protein Tyrosine Phosphatase， Non-Receptor Type Substrate 1，Tyrosine-Protein Phosphatase Non-Receptor Type Substrate 1，Tyrosine Phosphatase SHP Substrate 1，Signal-Regulatory Protein Alpha-3，Signal-Regulatory Protein Alpha，SHP Substrate 1，CD172a Antigen，Sirp-Alpha-1，Sirp-Alpha-2，MYD-1，Bit，SIRPalpha，SIRPalpha2 |
| Approved Drugs | 2 |
| Drugs in Clinical Trials | 19 |
| Highest Development Stage | Approved |
SIRP alpha Product List
- Product Category
Protein (19)Cell (1)
- Product Status
Launched (20)
- Species
Human (9)Mouse (6)Cynomolgus (4)Rat (1)
- Tag
Fc Tag (5)Mouse IgG Fc Tag (2)His Tag (4)Fc Tag & Avi Tag (3)His Tag & Avi Tag (3)Mouse IgG Fc Tag & Avi Tag (1)Llama IgG Fc Tag (1)- (1)
- Conjugate
Unconjugated (10)Biotin-labeled (7)PE Labeled (2)- (1)
Total: 20
- 1
- 2
SIRP alpha Background
Tyrosine-protein phosphatase non-receptor type substrate 1 (SHPS1) is also known as CD172 antigen-like family member A (CD172a), Macrophage fusion receptor, MyD-1 antigen, Signal-regulatory protein alpha (SIRPA or SIRP alpha) or p84, is a member of the SIRP family, and also belongs to the immunoglobulin superfamily. SIRP alpha is Ubiquitous and highly expressed in brain. SIRPA / CD172a is immunoglobulin-like cell surface receptor for CD47 and acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. SIRPA / SHPS-1 supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment and may play a key role in intracellular signaling during synaptogenesis and in synaptic function By similarity. SIRPA / MyD1 involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin and mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47 binding prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells.
SIRP alpha Synonyms
SHPS1,SIRPA,CD172A,BIT,MFR,MYD1,P84,PTPNS1
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ipsoprubart | ELA-026 | Phase 3 Clinical | Electra Therapeutics Inc | Lymphohistiocytosis, Hemophagocytic; Neoplasms | Details |
| LM-101 | LM-101 | Phase 2 Clinical | LaNova Medicines Ltd | Hematologic Neoplasms; Leukemia; Neoplasms; Solid tumours | Details |
| HX-044 | HX044; HX-044 | Phase 2 Clinical | Hanx Biopharmaceuticals Pty Ltd | Lymphoma; Solid tumours | Details |
| BRB-002 | BRB-002 | Phase 2 Clinical | Bitterroot Bio Inc | Atherosclerosis; Cardiovascular Diseases; Vasculitis | Details |
| BI-770371 | BI-770371 | Phase 2 Clinical | Ose Immunotherapeutics | Carcinoma, Non-Small-Cell Lung; Liver Cirrhosis; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| IBC-0966 | IBC-0966 | Phase 2 Clinical | Neoplasms | Details | |
| HX-009 | HX-009; HX009-II-02 | Phase 2 Clinical | Waterstone Hanxbio Pty Ltd | Bile Duct Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms; Lymphoma; Melanoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| BI-765063 | OSE-172; BI-765063; Effi-DEM | Phase 1 Clinical | Effimune | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| ADU-1805 | ADU-1805 | Phase 1 Clinical | Aduro Biotech Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Solid tumours | Details |
| Q-1801 | Q-1801; Q 1801 | Phase 1 Clinical | Qure Biotechnology (Shanghai) Co Ltd | Solid tumours | Details |
| Recombinant humanized IgG4 anti-SIRPα antibody（Daiichi Sankyo） | DS-1103a | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Breast Neoplasms; Solid tumours | Details |
| JY-47 | JY47; JY-47 | Phase 1 Clinical | Hangzhou Jiuyuan Gene Biomedical Co Ltd | Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Solid tumours | Details |
| BYON-4228 | BYON-4228 | Phase 1 Clinical | Sanquin Blood Supply Foundation | Lymphoma; Solid tumours | Details |
| BSI-082 | BSI-082 | Phase 1 Clinical | Biosion Inc | Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours | Details |
| BR-105 | BR-105; BR105 | Phase 1 Clinical | Hisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co Ltd | Lymphoma, Large B-Cell, Diffuse; Neoplasms | Details |
| [89Zr]Zr- BI-765063(Boehringer Ingelheim) | Phase 1 Clinical | Boehringer Ingelheim Corp | Carcinoma, Non-Small-Cell Lung; Melanoma; Squamous Cell Carcinoma of Head and Neck | Details | |
| TQB-2928 | TQB-2928 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Osteosarcoma; Solid tumours | Details |
| BI-765080 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Details | ||
| ES-004 | ES-004; ES 004-N4; ES 004-B4 | Phase 1 Clinical | Elpiscience (Shanghai) Biopharma Ltd | Neoplasms; Solid tumours | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Relugolix/Estradiol/Norethindrone Acetate | E2/NETA | Approved | Myovant Sciences | MYFEMBREE, RYEQO | United States | Menorrhagia; Leiomyoma | Sumitomo Pharma America Inc, Myovant Sciences | 2021-05-26 | Endometriosis; Leiomyoma; Menorrhagia; Pain; Uterine Neoplasms | Details |
| Elagolix/estradiol/norethindrone acetate | Approved | Abbvie Inc | Oriahnn | United States | Menorrhagia | Abbvie Inc | 2020-05-29 | Menorrhagia | Details |
Product Reviews
R***n2024-06-03
0People LikeI recently used the PE-Labeled Human SIRP alpha / CD172a Protein, Fc Tag for detecting the expression of CD47 in Jurkat T-cells and primary T-cells, and I am very pleased with the results. The SIRP alpha reagent effectively binds to CD47 overexpressed in both Jurkat and primary T-cells. This experiment was conducted to demonstrate the overexpression of CD47 in T-cells, using the anti-CD47 antibody (clone: CC2C6) to confirm the expression. Additionally, it was crucial to show that our CD47 can bind to its natural ligand, SIRP alpha. The reagent performed excellently in this regard, providing clear and reliable results. I've attached an image showing the data with a CD47 KO Jurkat cell line, further validating the specificity and effectiveness of this reagent. Overall, I highly recommend this product for CD47 detection and binding studies.- J***r2022-08-18 0People LikeI used this SIRPa-PE Fc tag for a FACS assay using the recommended SOP provided by Acro and our rep Nik Kamachi. Nik was very helpful in providing insight on the capabilities of Acro to provide custom labeled SIRPa Fc tags to meet our needs for small molecule screening assays that are FACS and IF-based. The human SIRPa-PE Fc tag was very easy to use and gave a strong signal with both flow cytometry and imaging
- M***g2022-05-07 1People LikeWe purchased the SIRP-alpha-Fc protein for CD47 competition studies via BLI. The protein was delivered quickly and easy to resuspend following the instructions in the COA. We observed strong binding for this protein to CD47 and minimal background binding to the sensors. We were also able to demonstrate competition with commercially available antibodies. Overall, this product specifically binds CD47 and worked well in BLI based competition assays.
Load More
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland